Table 3 Treatment features of LISA group compared to control group in the first week of life
LISA (n = 169) | Control (n = 155) | p-value | |
|---|---|---|---|
Surfactant | |||
Multiple gifts | 55 (32.5%) | 33 (21.3%) | 0.023* |
≥ 1 endotracheal tube gift | 35 (20.7%) | 155 (100%) | < 0.001* |
Initial dose (mg/kg), median (IQR) | 189 (162–207) | 148 (126–174) | < 0.001* |
Total dose (mg/kg), median (IQR) | 208 (178–329) | 160 (129–198) | < 0.001* |
Respiratory support | |||
Intubation | 65 (38.5%) | 155 (100%) | < 0.001* |
MV 12 h | 60 (35.5%) | 119 (76.8%) | < 0.001* |
MV (days), median (IQR) | 0.0 (0–1) | 1.0 (1–3) | < 0.001* |
Drug prescriptions | |||
Morphine | 20 (11.8%) | 23 (14.8%) | 0.426 |
Midazolam | 3 (1.8%) | 1 (0.6%) | 0.358 |
Inotropes | 16 (9.5%) | 28 (18.1%) | 0.024* |
Insulin | 8 (4.7%) | 13 (8.4%) | 0.182 |
Antibiotics for suspected EOS (days), median (IQR) | 3 (2–6) | 5 (3–7) | < 0.001* |
PDA treatment courses | 0.658 | ||
None | 91 (53.8%) | 84 (54.2%) | |
1 | 46 (27.2%) | 35 (22.6%) | |
> 1 | 32 (18.9%) | 36 (23.2%) | |
Erythrocyte transfusions | 0.003* | ||
None | 127 (75.1%) | 90 (58.1%) | |
1 | 23 (13.6%) | 37 (23.9%) | |
> 1 | 19 (11.2%) | 28 (18.1%) | |
Thrombocyte transfusions | 0.458 | ||
None | 153 (90.5%) | 136 (87.7%) | |
1 | 10 (5.9%) | 12 (7.7%) | |
> 1 | 6 (3.6%) | 7 (4.5%) | |
Enteral feeding (mL/kg), median (IQR) | |||
Day 5 | 88 (50–120) | 60 (40–120) | 0.051 |
Day 7 | 120 (80–160) | 100 (60–140) | 0.048* |
Umbilical catheter | 64 (37.9%) | 80 (51.6%) | 0.013* |
Phototherapy (days), mean (SD) | 2.1 (1.8) | 2.1 (1.6) | 0.826 |